AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28117378 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS over the medial prefrontal cortex (mPFC) in females
Number of subjects: 32
Study 28117378 — intervention group
Group type: COMPARATOR
Intervention: Placebo tDCS over the medial prefrontal cortex (mPFC) in females
Number of subjects: 32
Study 28117378 — intervention group
Group type: COMPARATOR
Intervention: Anodal tDCS over the vertex in females
Number of subjects: 32
Study 28117378 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS over the medial prefrontal cortex (mPFC) in males
Number of subjects: 32
Study 28117378 — intervention group
Group type: COMPARATOR
Intervention: Placebo tDCS over the vertex in males
Number of subjects: 32
Study 24947812 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric training with vibration (ST+VT)
Number of subjects: 24
Study 24947812 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric training without vibration (ST)
Number of subjects: 24
Study 24947812 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 24
Study 23154577 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprandial exercise (walking on a motorized treadmill at ca. 50%V(·)o(2)max for 30 min) after glucose intake
Number of subjects: 0
Study 23154577 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprandial exercise (walking on a motorized treadmill at ca. 50%V(·)o(2)max for 30 min) after glucose with OFTT cream intake
Number of subjects: 0
Study 23154577 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprandial exercise
Number of subjects: 0
Study 21632504 — intervention group
Group type: EXPERIMENTAL
Intervention: Id vaccine (Id-KLH + GM-CSF)
Number of subjects: 177
Study 21632504 — intervention group
Group type: COMPARATOR
Intervention: Control (KLH + GM-CSF)
Number of subjects: 177
Study 21632504 — intervention group
Group type: EXPERIMENTAL
Intervention: IgM-Id vaccine
Number of subjects: 177
Study 21632504 — intervention group
Group type: COMPARATOR
Intervention: Isotype-matched control
Number of subjects: 177
Study 21632504 — intervention group
Group type: EXPERIMENTAL
Intervention: IgG-Id vaccine
Number of subjects: 177
Study 19098687 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg/d of dehydroepiandrosterone
Number of subjects: 20
Study 19098687 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 17101607 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2 g amino acids, 1.2 g glycerol, and 0.5 g fat emulsion/kg/day (approximately 15 kcal/kg/day)
Number of subjects: 30
Study 17101607 — intervention group
Group type: COMPARATOR
Intervention: 1.2 g amino acids, 1.5 g dextrose, and 0.5 g fat emulsion/kg/day (approximately 15 kcal/kg/day)
Number of subjects: 30
Study 15551695 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 11694202 — intervention group
Group type: EXPERIMENTAL
Intervention: Cessation trial participants
Number of subjects: 401
Study 11694202 — intervention group
Group type: COMPARATOR
Intervention: General population chewers
Number of subjects: 401
Study 9203190 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEPO 50 U/kg once a week (group 1)
Number of subjects: 20
Study 9203190 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEPO 150 U/kg three times a week (group 2)
Number of subjects: 20
Study 7929736 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic texture score
Number of subjects: 95
Study 7929736 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic testicular volume
Number of subjects: 95
Study 7929736 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic volume
Number of subjects: 95
Study 7929736 — intervention group
Group type: EXPERIMENTAL
Intervention: Sperm count
Number of subjects: 95
Study 3602843 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin (100, 150, and 200 mcg/kg)
Number of subjects: 0
Study 3602843 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3602843 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin
Number of subjects: 0
Study 29468854 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone
Number of subjects: 20
Study 29468854 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 20
Study 29468854 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 27571249 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 2000 mg daily
Number of subjects: 62
Study 27571249 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 24598116 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactated Ringer's solution
Number of subjects: 74
Study 24598116 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline solution
Number of subjects: 74
Study 24598116 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 74
Study 22688848 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based intervention with five interrelated components designed to reduce underage access to alcohol.
Number of subjects: 36
Study 22688848 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity implementation of underage drinking law enforcement.
Number of subjects: 36
Study 22688848 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced enforcement of underage drinking laws.
Number of subjects: 36
Study 22688848 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned).
Number of subjects: 36
Study 20006290 — intervention group
Group type: EXPERIMENTAL
Intervention: Anma therapy (40-min session)
Number of subjects: 15
Study 20006290 — intervention group
Group type: COMPARATOR
Intervention: Rest intervention (40-min session)
Number of subjects: 15
Study 18200453 — intervention group
Group type: EXPERIMENTAL
Intervention: Probatory CPAP therapy with follow-up examination
Number of subjects: 249
Study 18200453 — intervention group
Group type: COMPARATOR
Intervention: Immediate prescription of CPAP device
Number of subjects: 249
Study 18200453 — intervention group
Group type: EXPERIMENTAL
Intervention: Probatory CPAP therapy
Number of subjects: 249
Study 15239144 — intervention group
Group type: EXPERIMENTAL
Intervention: High observed adenoma detection rates at surveillance
Number of subjects: 0
Study 15239144 — intervention group
Group type: EXPERIMENTAL
Intervention: Low observed colorectal cancer incidence
Number of subjects: 0
Study 15239144 — intervention group
Group type: EXPERIMENTAL
Intervention: Colorectal cancer screening strategies focusing on adenoma detection
Number of subjects: 0
Study 12575587 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy combined with anti-tumor drugs
Number of subjects: 162
Study 12575587 — intervention group
Group type: COMPARATOR
Intervention: Control group (no music therapy)
Number of subjects: 162
Study 9099469 — intervention group
Group type: EXPERIMENTAL
Intervention: Apomorphine
Number of subjects: 12
Study 9099469 — intervention group
Group type: COMPARATOR
Intervention: Dispersible Madopar
Number of subjects: 12
Study 8555639 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacomechanical thrombolysis
Number of subjects: 146
Study 8555639 — intervention group
Group type: COMPARATOR
Intervention: Surgical thrombectomy
Number of subjects: 146
Study 3475036 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxacin 600 mg, single dose
Number of subjects: 20
Study 3475036 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxacin 400 mg, single dose
Number of subjects: 20
Study 3475036 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxacin 400 mg every 12 h, four doses
Number of subjects: 20
Study 3475036 — intervention group
Group type: EXPERIMENTAL
Intervention: All enoxacin doses
Number of subjects: 20
Study 30597504 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-g oral TXA 2 hours pre-operatively followed by 1-g oral TXA 3 hours post-operatively (group B)
Number of subjects: 240
Study 30597504 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-g oral TXA followed by 1-g oral TXA 3 and 7 hours post-operatively (group C)
Number of subjects: 240
Study 30597504 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-g oral TXA followed by 1-g oral TXA 3, 7 and 11 hours post-operatively (group D)
Number of subjects: 240
Study 30597504 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-g oral TXA followed by 1-g oral TXA 3, 7, 11 and 15 hours post-operatively (group E)
Number of subjects: 240
Study 30597504 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo (control group A)
Number of subjects: 240
Study 30390675 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicinal plants used by local community
Number of subjects: 78
Study 30390675 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional medicinal plant knowledge
Number of subjects: 78
Study 27005659 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid fortified flour
Number of subjects: 16648
Study 27005659 — intervention group
Group type: COMPARATOR
Intervention: Ordinary flour (Control)
Number of subjects: 16648
Study 25226009 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin-BP 3.75%
Number of subjects: 498
Study 25226009 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 498
Study 22565161 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily MMX mesalamine 2.4 g/day
Number of subjects: 826
Study 22565161 — intervention group
Group type: COMPARATOR
Intervention: Twice-daily delayed-release mesalamine 1.6 g/day
Number of subjects: 826
Study 22565161 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 826
Study 19838864 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthetic injection (2 ml lidocaine of 1%)
Number of subjects: 80
Study 19838864 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry needling on trigger points
Number of subjects: 80
Study 18058494 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 80 mg at Week 0 and 40 mg every other week from Week 1 to Week 15
Number of subjects: 0
Study 16343396 — intervention group
Group type: EXPERIMENTAL
Intervention: Tisseel
Number of subjects: 56
Study 16343396 — intervention group
Group type: COMPARATOR
Intervention: Non-Tisseel
Number of subjects: 56
Study 11747061 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation training
Number of subjects: 0
Study 11747061 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation training offered independently of medical treatment
Number of subjects: 0
Study 9205767 — intervention group
Group type: EXPERIMENTAL
Intervention: ebrotidine 400 mg/day
Number of subjects: 30
Study 9205767 — intervention group
Group type: EXPERIMENTAL
Intervention: ebrotidine 800 mg/day
Number of subjects: 30
Study 9205767 — intervention group
Group type: EXPERIMENTAL
Intervention: ranitidine 150 mg/day
Number of subjects: 30
Study 9205767 — intervention group
Group type: EXPERIMENTAL
Intervention: ranitidine 300 mg/day
Number of subjects: 30
Study 9205767 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study 7970506 — intervention group
Group type: EXPERIMENTAL
Intervention: Taxol 135 mg/m2
Number of subjects: 471
Study 7970506 — intervention group
Group type: EXPERIMENTAL
Intervention: Taxol 175 mg/m2
Number of subjects: 471
Study 7970506 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 471
Study 3620002 — intervention group
Group type: EXPERIMENTAL
Intervention: Beck depression scale (1, 2, or 3 occasions)
Number of subjects: 60
Study 3620002 — intervention group
Group type: EXPERIMENTAL
Intervention: Zung depression scale (1, 2, or 3 occasions)
Number of subjects: 60
Study 3620002 — intervention group
Group type: COMPARATOR
Intervention: Initial test administration (Beck and Zung scales)
Number of subjects: 60
Study 30508645 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum 25-hydroxyvitamin D levels categorized in four groups: <25.0, 25.0-49.9, 50.0-74.9, and ≥75.0 nmol/L (highest group as reference)
Number of subjects: 5110
Study 30508645 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with arthritis (n=1732)
Number of subjects: 5110
Study 30508645 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with depression (n=528)
Number of subjects: 5110
Study 28287413 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose Supplement (FS)
Number of subjects: 10
Study 28287413 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose Supplement (GS)
Number of subjects: 10
Study 28287413 — intervention group
Group type: COMPARATOR
Intervention: Fructose Control (FC)
Number of subjects: 10
Study 28287413 — intervention group
Group type: COMPARATOR
Intervention: Glucose Control (GC)
Number of subjects: 10
Study 24853650 — intervention group
Group type: EXPERIMENTAL
Intervention: MST
Number of subjects: 20
Study 24853650 — intervention group
Group type: COMPARATOR
Intervention: ECT
Number of subjects: 20
Study 24483106 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenling Fuzheng Capsule (SFC) or Qingdu Capsule (QC)
Number of subjects: 220
Study 24483106 — intervention group
Group type: COMPARATOR
Intervention: SFC or QC combined with highly active antiretroviral agents
Number of subjects: 220
Study 22051498 — intervention group
Group type: EXPERIMENTAL
Intervention: High fluoride intake and heavy force
Number of subjects: 48
Study 22051498 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fluoride intake and heavy force
Number of subjects: 48
Study 22051498 — intervention group
Group type: EXPERIMENTAL
Intervention: High fluoride intake and light force
Number of subjects: 48
Study 22051498 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fluoride intake and light force
Number of subjects: 48
Study 19903376 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg/day of aspirin
Number of subjects: 121
Study 19903376 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg/day of aspirin
Number of subjects: 121
Study 19903376 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study 17011743 — intervention group
Group type: EXPERIMENTAL
Intervention: Semantic (animal) fluency task
Number of subjects: 153
Study 17011743 — intervention group
Group type: EXPERIMENTAL
Intervention: Letter (S and P) fluency task
Number of subjects: 153
Study 17011743 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of semantic fluency and narrative recall
Number of subjects: 153
Study 15491387 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy of enalapril and losartan (Group A)
Number of subjects: 9
Study 15491387 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group B)
Number of subjects: 9
Study 11080322 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermoluminescent dosimeter (TLD) measurements of radiation dose to the skin and whole body over the lead apron.
Number of subjects: 235
Study 11080322 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermoluminescent dosimeter (TLD) measurements of radiation dose to the whole body under the lead apron.
Number of subjects: 235
Study 9282076 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Care Plan Guide
Number of subjects: 1827
Study 8342744 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (10 micrograms/kg i.v.) and droperidol (75 micrograms/kg i.v.) before the beginning of surgery (Group A)
Number of subjects: 100
Study 8342744 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (10 micrograms/kg i.v.) before the beginning, droperidol (75 micrograms/kg i.v.) after completion of surgery (Group B)
Number of subjects: 100
Study 8342744 — intervention group
Group type: EXPERIMENTAL
Intervention: No atropine, droperidol (75 micrograms/kg i.v.) before the beginning of surgery (Group C)
Number of subjects: 100
Study 8342744 — intervention group
Group type: EXPERIMENTAL
Intervention: No atropine, droperidol (75 micrograms/kg i.v.) after completion of surgery (Group D)
Number of subjects: 100
Study 8342744 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (10 micrograms/kg i.v.)
Number of subjects: 100
Study 8342744 — intervention group
Group type: COMPARATOR
Intervention: No atropine
Number of subjects: 100
Study 8342744 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol (75 micrograms/kg) timing
Number of subjects: 100
Study 8342744 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (10 micrograms/kg) prior to surgery
Number of subjects: 100
Study 8342744 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (10 micrograms/kg)
Number of subjects: 100
Study 8342744 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger children (3 to 6 years)
Number of subjects: 100
Study 8342744 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with more than two eye muscles repaired
Number of subjects: 100
Study 8342744 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery scores
Number of subjects: 100
Study 25646022 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief behavioral sleep intervention (2 clinical consultations and a follow-up phone call covering sleep hygiene and standardized behavioral strategies)
Number of subjects: 61
Study 25646022 — intervention group
Group type: COMPARATOR
Intervention: Usual clinical care
Number of subjects: 61
Study 30062709 — intervention group
Group type: EXPERIMENTAL
Intervention: Quercetin 1,000 mg/day for 12 weeks
Number of subjects: 78
Study 27501900 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-low-dose CT (ULDCT) (100 kVp ± 20 and 10 mAs)
Number of subjects: 133
Study 27501900 — intervention group
Group type: COMPARATOR
Intervention: Low-dose computed tomography (LDCT) (100 kVp and 60 mAs)
Number of subjects: 133
Study 24567266 — intervention group
Group type: EXPERIMENTAL
Intervention: Hands-on virtual reality (VR) intervention
Number of subjects: 258
Study 24567266 — intervention group
Group type: COMPARATOR
Intervention: Pre-VR intervention (prior to lecture)
Number of subjects: 258
Study 22405632 — intervention group
Group type: EXPERIMENTAL
Intervention: TARGET (Targeted Left Ventricular Lead Placement)
Number of subjects: 220
Study 22405632 — intervention group
Group type: COMPARATOR
Intervention: Control (standard unguided CRT)
Number of subjects: 220
Study 20578205 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein diet (1.34 g/kg body weight)
Number of subjects: 67
Study 20578205 — intervention group
Group type: COMPARATOR
Intervention: Conventional protein diet (0.8 g/kg body weight)
Number of subjects: 67
Study 20578205 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein diet
Number of subjects: 67
Study 20578205 — intervention group
Group type: COMPARATOR
Intervention: Conventional protein diet
Number of subjects: 67
Study 18385992 — intervention group
Group type: COMPARATOR
Intervention: Stented group (21 patients)
Number of subjects: 43
Study 18385992 — intervention group
Group type: EXPERIMENTAL
Intervention: Unstented group (22 patients)
Number of subjects: 43
Study 16404866 — intervention group
Group type: EXPERIMENTAL
Intervention: ARTRA (500 mg glucosamine hydrochloride + 500 mg chondroitine sulphate) taken 1 tablet 2 times a day for the first month, then 1 tablet a day for the following 5 months, along with diclofenac sodium 50 mg 2 times a day with gradual decrease as pain decreased.
Number of subjects: 90
Study 16404866 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac sodium 50 mg twice a day for 6 months (control group).
Number of subjects: 90
Study 12892444 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthetic with N2O:O2
Number of subjects: 60
Study 12892444 — intervention group
Group type: COMPARATOR
Intervention: Local anesthetic only
Number of subjects: 60
Study 12892444 — intervention group
Group type: EXPERIMENTAL
Intervention: Gow‐Gates/standard block, standard block/Vazirani‐Akinosi, Gow‐Gates/Vazirani‐Akinosi
Number of subjects: 60
Study 10470627 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 2.0 mg/kg i.v. followed by continuous infusion of 170 micrograms kg‐1 min‐1 (with additional 0.5 mg/kg if needed)
Number of subjects: 60
Study 10470627 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane 5% inhalation
Number of subjects: 60
Study 8934168 — intervention group
Group type: EXPERIMENTAL
Intervention: Detachable snare
Number of subjects: 89
Study 8934168 — intervention group
Group type: COMPARATOR
Intervention: Conventional polypectomy without detachable snare
Number of subjects: 89
Study 1989740 — intervention group
Group type: EXPERIMENTAL
Intervention: Promethazine (0.5 mg.kg‐1 IV + 0.5 mg.kg‐1 IM)
Number of subjects: 100
Study 1989740 — intervention group
Group type: COMPARATOR
Intervention: Droperidol (0.075 mg.kg‐1 IV + physiological saline, 0.02 ml.kg‐1 IM)
Number of subjects: 100
Study 1989740 — intervention group
Group type: EXPERIMENTAL
Intervention: Promethazine
Number of subjects: 100
Study 1989740 — intervention group
Group type: COMPARATOR
Intervention: Droperidol
Number of subjects: 100
Study 6137231 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 6
Study 6137231 — intervention group
Group type: EXPERIMENTAL
Intervention: Practolol
Number of subjects: 6
Study 6137231 — intervention group
Group type: COMPARATOR
Intervention: Atropine (0.04 mg/kg)
Number of subjects: 6
Study 28902116 — intervention group
Group type: EXPERIMENTAL
Intervention: Preconditioning exercise with WBV (40 Hz, 2 mm)
Number of subjects: 14
Study 28902116 — intervention group
Group type: COMPARATOR
Intervention: Preconditioning exercise without WBV
Number of subjects: 14
Study 28902116 — intervention group
Group type: EXPERIMENTAL
Intervention: Both conditions (WBV and no WBV)
Number of subjects: 14
Study 30591380 — intervention group
Group type: EXPERIMENTAL
Intervention: Mankai
Number of subjects: 36
Study 30591380 — intervention group
Group type: COMPARATOR
Intervention: Soft cheese
Number of subjects: 36
Study 30591380 — intervention group
Group type: COMPARATOR
Intervention: Green peas
Number of subjects: 36
Study 27923685 — intervention group
Group type: EXPERIMENTAL
Intervention: LVR with CDCs (Group 1)
Number of subjects: 28
Study 27923685 — intervention group
Group type: COMPARATOR
Intervention: LVR with vehicle solution (Group 2)
Number of subjects: 28
Study 27923685 — intervention group
Group type: COMPARATOR
Intervention: Vehicle solution without LVR (Group 3)
Number of subjects: 28
Study 26758937 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid supplementation
Number of subjects: 48
Study 26758937 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 24079647 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (4 group sessions)
Number of subjects: 83
Study 24079647 — intervention group
Group type: COMPARATOR
Intervention: Standard care group
Number of subjects: 83
Study 23516864 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of phospholipid nanoparticles
Number of subjects: 0
Study 23516864 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0